GlaxoSmithKline hit with new accusations it bribed doctors in Syria to boost sales
Glaxosmithkline has been hit with fresh claims it bribed doctors and other medical officials to boost sales of its medicines – this time in Syria.
The drug maker, which is already under investigation for similar allegations in China, Poland and Jordan, is said to have been informed of the alleged misdeeds at its non-prescription drugs business via an anonymous email sent to bosses last week and seen by the Reuters news agency.
The company confirmed it received the email on August 6, adding it had ‘zero tolerance for any kind of unethical behaviour’.
Problems: The drug maker is already under investigation for similar allegations in China, Poland and Jordan
‘All the claims in this email will be thoroughly investigated using internal and external resources as part of our ongoing investigation into operations in Syria,’ it said.
‘We are committed to taking any disciplinary actions resulting from the findings.'
GSK has suspended its relationship with distributors in Syria while it investigates the claims. Shares were flat at 1377.5p.
Most watched Money videos
- Land Rover unveil newest all-electric Range Rover SUV
- Alfa Romeo reveals first electric sporty SUV Junior for Alfisti fans
- 'Now even better': Nissan Qashqai gets a facelift for 2024 version
- Tesla unveils new Model 3 Performance - it's the fastest ever!
- Mini celebrates the release of brand new all-electric car Mini Aceman
- Mini Cooper SE: The British icon gets an all-electric makeover
- Paul McCartney's psychedelic Wings 1972 double-decker tour bus
- Top Gear takes Jamiroquai's lead singer's Lamborghini for a spin
- Incredibly rare MG Metro 6R4 rally car sells for a record £425,500
- A look inside the new Ineos Quartermaster off-road pickup truck
- Kia's 372-mile compact electric SUV - and it could costs under £30k
- Introducing Britain's new sports car: The electric buggy Callum Skye
- Outrage at Ofwat plans to cut sewage-dumping fines for...
- Boost for sunseekers as pound hits highest level against...
- ECB set to press ahead with rate cut next week thanks to...
- Nightcap walks away from acquisition of Revolution Bars
- BUSINESS LIVE: Dr Martens US sales slump; Nightcap...
- Britain for sale, again? De La Rue in talks over sale of...
- Homeownership among under 35s hits highest level since...
- City fails to back £3.6bn Royal Mail takeover - despite...
- NS&I quietly boosts rate on two of its savings accounts...
- London markets 'less attractive' than international...
- Smart meter installations fall 10% as energy firms...
- Royal Mail's shameful sale: Debt-fuelled deal is bad for...
- MARKET REPORT: International Workplace Group plunges as...
- BHP abandons £39bn pursuit of Anglo American as City...
- Vaccines tsar sells biotech start-up to US pharma group...
- Dr Martens to slash £25m in costs amid US demand slump
- Big Help for Home REIT: Property firm reclaims more than...
- Marks and Spencer appoints Rightmove's Alison Dolan as...